CGON: CG Oncology Inc Company Value to Net Income

CG Oncology Inc - graphic logo of issuer CGON

CG Oncology, Inc. (CGON) is a leading biotech pioneer focusing its R&D capabilities on developing viral drugs for tumor immunotherapy. The company's quarterly P/E ratio illustrates the dynamics of market value relative to earnings, while -31.30 captures the current state of this parameter. The development strategy relies on synergy with medical centers for bladder cancer treatment and is protected by patents alongside FDA support.

Price to Earnings Ratio: CG Oncology, Inc. (CGON) for 11/14/2024 - 11/17/2026

Comprehensive metric breakdowns and analytics for CG Oncology Inc (CGON)

- market capitalization information:
Summary company analysis:CGON CG Oncology
Flagship merchandise of CG Oncology

The resilience of CG Oncology, Inc. (CGON) is based on oncology clinical trial results, which remain independent of market cyclicality. By analyzing the company's current P/E ratio, an investor can see the relationship between market capitalization and net income, allowing for an assessment of the price premium relative to actual earnings and the determination of a fair entry point into the asset.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|URGN - Price to Earnings Ratio|BCAX: Price to Earnings Ratio|PSNL - P/E Multiple|Erasca Corp (ERAS) - Price to Earnings Ratio|Delcath - Company Value to Net Income|YMAB (Y-mAbs Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Aura Biosciences, Inc. AURA|P/E Multiple CADL|P/E Multiple Accuray (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group Inc. SLS|ACTU - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV